Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel, ISTART Review.                    

*Date:*                         February 1, 2008.                    

*Time:*                         1 p.m. to 5 p.m.                              ( print page 1632)    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Virtual Meeting).                    

*Contact Person:*                         Mark Swieter, PhD, Chief, Training and Special Projects Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6101 Executive Boulevard, Suite 200, Bethesda, MD 20892-8401, (301) 435-1389,                         *ms80x@nih.gov*.                    

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel, NIDA F New Investigator R01 Member Conflicts.                    

*Date:*                         February 15, 2008.                    

*Time:*                         12 p.m. to 3 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).                    

*Contact Person:*                         Gerald L. McLaughlin, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892-8401, 301-402-6626,                         *gm145a@nih.gov*.                    

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel, NIDA-F New Investigator R01s Sep.                    

*Date:*                         February 15, 2008.                    

*Time:*                         12 p.m. to 6 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).                    

*Contact Person:*                         Meenaxi Hiremath, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301-402-7964,                         *mh392g@nih.gov*.                     

*Name of Committee:*                         National Institute on Drug Abuse Initial Review Group, Health Services Research Subcommittee.                    

*Date:*                         March 4-5, 2008.                    

*Time:*                         8:30 a.m. to 6:30 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Jurys Washington Hotel, 1500 New Hampshire Ave. NW., Washington, DC 20036.                    

*Contact Person:*                         Meenaxi Hiremath, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301-402-7964,                         *mh392g@nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Initial Review Group, Treatment Research Subcommittee.                    

*Date:*                         March 4-5, 2008.                    

*Time:*                         9 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Jurys Washington Hotel, 1500 New Hampshire Avenue, NW., Washington, DC 20036.                    

*Contact Person:*                         Kesinee Nimit, MD., Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-8401, (301) 435-1432.                    

*Name of Committee:*                         National Institute on Drug Abuse Initial Review Group, Training and Career Development Subcommittee.                    

*Date:*                         March 11-13, 2008.                    

*Time:*                         9 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, DC 20037.                    

*Contact Person:*                         Eliane Lazar-Wesley, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6101 Executive Boulevard, Room 220, MSC 8401, Bethesda, MD 20892-8401, 301-451-4530,                         *el6r@nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Initial Review Group, Medication Development Research Subcommittee.                    

*Date:*                         March 13, 2008.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Omni Shoreham Hotel, 2500 Calvert Street, NW., Washington, DC 20008.                    

*Contact Person:*                         Gerald L. McLaughlin, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-8401, 301-402-6626,                         *gm145a@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: January 3, 2008.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 08-43  Filed 1-8-08; 8:45 am]

BILLING CODE 4140-01-M